Skip to main content
. 2016 Mar 30;6(1):125–131. doi: 10.3233/JPD-150712

Fig.2.

Fig.2

Medication class contributions. (A) Average relative contributions of medication classes to total LEDD (mg) over the two-year study period. (B) Average change from baseline for LEDD (mg) by medication class. (C) Proportion of subjects prescribed more than one type of PD medication (polypharmacy) at baseline and each six-month visit. n.s. = not significant, *=p <  0.05.